2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-132596A
    Tivanisiran sodium 1848239-71-3
    Tivanisiran sodium is a siRNA used for the study of dry eye disease. Tivanisiran sodium was designed to silence transient receptor potential vanilloid 1 (TRPV1) mRNA.
    Tivanisiran sodium
  • HY-N0473S2
    L-Tyrosine-13C6 201595-63-3 99.90%
    L-Tyrosine-13C6 is the 13C-labeled L-Tyrosine. L-Tyrosine is a non-essential amino acid which can inhibit citrate synthase activity in the posterior cortex.
    L-Tyrosine-13C6
  • HY-W014941
    (R)-(-)-α-Methylhistamine dihydrochloride 75614-89-0 ≥99.0%
    (R)-(-)-α-Methylhistamine dihydrochloride is a potent, selective and brain-penetrant agonist of H3 histamine receptor, with a Kd of 50.3 nM. (R)-(-)-α-Methylhistamine dihydrochloride can enhance memory retention, attenuates memory impairment in rats.
    (R)-(-)-α-Methylhistamine dihydrochloride
  • HY-W016443
    L-m-Tyrosine 587-33-7 ≥98.0%
    L-m-Tyrosine is an unnatural amino acid. L-m-Tyrosine reduces dopamine, norepinephrine and serotonin in rats. L-m-Tyrosine has potential in the research of Parkinsons disease, Alzheimers disease, and arthritis.
    L-m-Tyrosine
  • HY-W089835
    Sodium taurodeoxycholate hydrate 207737-97-1
    Sodium taurodeoxycholate hydrate is a bile salt-related anionic detergent. Sodium taurodeoxycholate hydrate is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Sodium taurodeoxycholate hydrate is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate-d6 (TDCA) exhibits anti-inflammatory and neuroprotective effects.
    Sodium taurodeoxycholate hydrate
  • HY-W181102
    NFAT Inhibitor-2 422546-87-0 98.02%
    NFAT Inhibitor-2 is a potent inhibitor of calcineurin NFAT signalling. Calcineurin is a serine/threonine protein phosphatase regulated by Ca2+ and calmodulin. NFAT Inhibitor-2 has the potential for the research of inflammatory disease, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a disease occurring with uncontrolled cell proliferation and/or differentiation, an angiogenesis-related disease, an allergy, anaphylaxis and alopecia (extracted from patent WO2016207212A1, compound 17).
    NFAT Inhibitor-2
  • HY-Y0966S2
    Glycine-2-13C 20220-62-6 99.3%
    Glycine-2-13C is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
    Glycine-2-13C
  • HY-B0914
    10-Undecenoic acid,98% (stabilized with TBC) 112-38-9 ≥98.0%
    10-Undecenoic acid (Undecylenic acid) is an antifungal agent. 10-Undecenoic acid inhibits Aβ oligomerization, scavenges ROS and inhibits μ-calpain activity. 10-Undecenoic acid has neuroprotective effects. 10-Undecenoic acid has anticancer effects on a variety of tumors. 10-Undecenoic acid inhibits C. albicans biofilm formation and MRSA infection. 10-Undecenoic acid inhibits quorum sensing signals of Bacillus subtilis and Pseudomonas aeruginosa.
    10-Undecenoic acid,98% (stabilized with TBC)
  • HY-N0850
    Benzoylhypaconine 63238-66-4 ≥99.0%
    Benzoylhypaconine (Benzoylhypacoitine) is a monoester Aconitum alkaloid, is the main pharmacologic and toxic component.
    Benzoylhypaconine
  • HY-P2048
    MOTS-c (human) 1627580-64-6 99.90%
    MOTS-c (human) is a blood-brain barrier-penetrating, mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders.
    MOTS-c (human)
  • HY-100907
    (±)-Acetylcarnitine chloride 2504-11-2 ≥99.0%
    (±)-Acetylcarnitine chloride (Acetyl dl-carnitine chloride) is a weak cholinergic agonist with cholinergic properties. (±)-Acetylcarnitine chloride is an important intermediate in lipid metabolism.
    (±)-Acetylcarnitine chloride
  • HY-117924
    AUTEN-67 1783800-77-0
    AUTEN-67 (Autophagy enhancer-67) is an orally active autophagy enhancer and MTMR14 inhibitor. AUTEN-67 has anti-aging and neuroprotective effects. AUTEN-67 protects neurons from stress-induced cell death. AUTEN-67 also restores nesting behavior in a mice model of Alzheimer disease.
    AUTEN-67
  • HY-139427
    3-Methylglutaconic acid 5746-90-7 99.60%
    3-Methylglutaconic acid is the major metabolites accumulating in 3-Methylglutaconic aciduria (MGTA). 3-Methylglutaconic acid can induce lipid oxidative damage and protein oxidative. 3-Methylglutaconic acid decreases the non-enzymatic antioxidant defenses in cerebral cortex supernatants to elicit oxidative stress in the cerebral cortex. 3-Methylglutaconic acid can be used for brain damage disease research.
    3-Methylglutaconic acid
  • HY-160505
    RO-275 2648837-04-9 ≥99.0%
    RO-275 (compound 29) is a potent, selective and orally active HCN1 inhibitor with IC50 values of 0.046, 14.3, 4.6, 13.9 µM for HCN1, HCN2, HCN3, HCN4, respectively. RO-275 rescues decremented working memory. RO-275 has the potential for the research of cognitive dysfunction in brain disorder.
    RO-275
  • HY-A0022A
    Azaphen dihydrochloride monohydrate 63302-99-8 99.94%
    Pipofezine(Azafen or Azaphen) is a potent inhibitor of the reuptake of serotonin.
    Azaphen dihydrochloride monohydrate
  • HY-P991047
    Anti-CD71/TfR1 Antibody ≥99.0%
    Anti-CD71/TfR1 Antibody (JR-141 antibody (uncoupled from iduronate 2-sulfatase)) is a humanized anti-human transferrin receptor (CD71; TfR) antibody. Anti-CD71/TfR1 Antibody is the antibody part of the fusion protein Pabinafusp alfa (HY-P99797). The recommend isotype control of Anti-CD71/TfR1 Antibody: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CD71/TfR1 Antibody
  • HY-W012848
    1-Phenylethanamine 618-36-0 99.14%
    1-Phenylethanamine is a potential central nervous system stimulant and a related compound of β-phenylethylamine. Due to the replacement of its benzene ring with an indole group, its brain glycogenolytic activity is significantly reduced. Therefore, 1-Phenylethanamine can be used to study the impact of the chemical structure of phenylethylamine derivatives on central nervous system activity. In addition, 1-Phenylethanamine can also be used to synthesize the tyrosine kinase (tyrosine kinase) inhibitor CLM3 (HY-164413).
    1-Phenylethanamine
  • HY-W100287
    Murrayafoline A 4532-33-6 99.73%
    Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline A has anti-neuroinflammatory activity.
    Murrayafoline A
  • HY-W176557
    TGN-073 877459-36-4
    TGN-073 is a facilitator of aquaporin-4 (AQP4), an astroglial water channel. TGN-073 reveals an increase of up to 41% in glymphatic transport in rat brain.
    TGN-073
  • HY-103230
    IEM-1460 121034-89-7 ≥98.0%
    IEM-1460 blocks both AMPA and NMDA glutamate receptor with anticonvulsant effect in vivo.
    IEM-1460
Cat. No. Product Name / Synonyms Application Reactivity